FILING ANALYSIS · MONDAY, NOVEMBER 16
Instil Bio, Inc. TIL — 8-K: Results of Operations and Financial Condition
neutral
Instil Bio's cash position of $67.1 million is expected to fund its operating plan through 2027, and the company reported a net loss of $4.2 million for the third quarter, which is an improvement from the $13.6 million net loss in the same period last year. However, the company's revenue and profitability are still uncertain, and the stock's price movement will likely be driven by future developme
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →